Advertisement

Topics

Search Results for "Mylan Atovaquone And Proguanil 250mg 100mg Tablet"

14:19 EST 26th February 2017 | BioPortfolio

Matching Channels

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

BRIEF-ANI Pharmaceuticals launchs Vancomycin HCL 125mg, 250mg capsules

* ANI Pharmaceuticals Inc - launch of Vancomycin HCL 125mg, 250mg capsules in a fifty count bottle

PERKIN ELMER TABLET AUTOSAMPLER FOR SPECTRUM ONE NTS TABLET AUTOSAMPLER SYSTEM

£375.00End Date: Sunday Feb-26-2017 11:49:53 GMTBuy It Now for only: £375.00Buy It Now | Add to watch list Biotech365 : PERKIN ELMER TABLET AUTOSAMPLER FOR SPECTRUM ONE NTS TABLET AUTOSAMPLER S...

FDA Accepts Mylan aBLA or Pegfilgrastim Biosimilar

Mylan N.V. and Biocon Ltd. have announced that the FDA has accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Amgen's Neulasta , for filing through the 351 ...

A look at a High Market Cap Stock: Mylan N.V., MYL

Mylan N.V., MYL is in the exchange NASDAQ and its industry is Drugs - Generic in the sector of Healthcare. Based in USA, Mylan N.V., MYL has a market cap of 19675.89.

Weak Outlook on Mylan

Mylan delivered 12.5% sales growth to $7.8 billion and -90% profit drop to $62.5 million. As observed, Mylan had an overall 40.6% growth in operating expenses.

Positive phase III results for Mylan’s biosimilar pegfilgrastim

Results of a study of Biocon and Mylan’s comparing Biocon/Mylan’s biosimilar pegfilgrastim (MYL-1401H) to the originator (Neulasta) has ‘demonstrated equivalent efficacy’, according to Mylan [...

Mylan N.V. (MYL) Downgraded to "Strong Sell" at Zacks Investment Research

According to Zacks, "There seems to be no end to Mylan's woes. Recently, 20 U.S. states filed a federal lawsuit against several generic drug makers including Mylan.

Mylan N.V. (MYL) Lowered to "Strong Sell" at Zacks Investment Research

According to Zacks, "There seems to be no end to Mylan's woes. Recently, 20 U.S. states filed a federal lawsuit against several generic drug makers including Mylan.

Matching PubMed Articles

Microstructure of Tablet-Pharmaceutical Significance, Assessment, and Engineering.

To summarize the microstructure - property relationship of pharmaceutical tablets and approaches to improve tablet properties through tablet microstructure engineering.

Transforming the Classroom With Tablet Technology.

Identifying the most effective models for integrating new technology into the classroom and understanding its effects on educational outcomes are essential for nurse educators. This article describes ...

HIV update: Which single-tablet regimens, and when.

With the approval of single-tablet regimens that contain 3 or 4 drugs, many patients take just one pill a day. So what are the options and what's on the horizon?

Investigation on Raman spectral features of a coated tablet under variation of its orientation respective to laser illumination and measurement of nominal coating thickness of packed tablets.

To investigate Raman spectral features of a coated biconvex tablet under variation of its orientation respective to laser illumination, spectra of the tablet were collected by illuminating laser on 12...

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.

Pill burden during antiretroviral treatment (ART) is associated with worse adherence and impaired virological suppression. We compared the effectiveness, tolerance, and persistence on treatment of sin...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement